What is the 13F Pro Quality Score for BLCO?

13F Pro ranks Bausch & Lomb Corp (BLCO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BLCO's current score at https://13fpro.ai/research/BLCO (free sign-up required for the full ranking).

Which hedge funds own the most BLCO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BLCO include DEUTSCHE BANK AG\, ICAHN CARL C, OAKTREE CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BLCO as soon as new 13F filings post.

Where does 13F Pro source BLCO data?

All Bausch & Lomb Corp fundamentals and ownership data come directly from SEC EDGAR. Bausch & Lomb Corp files with the SEC under CIK 1860742. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BLCO in?

Bausch & Lomb Corp (BLCO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BLCO research updated on 13F Pro?

BLCO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Bausch & Lomb Corp(BLCO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1860742 BLCO stock profile & AI dashboard →

13F Pro Quality Score

43.4/100

Rank #1,816 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

65.8/100

Profitability

26.5/100

Balance Sheet

28.1/100

Earnings Quality

30.0/100

Free Cash Flow

25.4/100

Institutional Flow

40.3/100

Revenue Scale

77.9/100

Dilution Risk

34.3/100

BLCO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Bausch & Lomb Corp (BLCO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BLCO at 43.4/100 on a 32-signal composite quality model, placing it at rank #1,816 of 2,879 stocks — the bottom half of the AI-ranked universe. BLCO scores in the top quartile across revenue scale (77.9). Areas of concern include free cash flow (25.4) and profitability (26.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 34.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Bausch & Lomb Corp reports quarterly revenue of $1.2B, net income of $-71.0M, an operating margin of 2.6%. Top institutional holders of BLCO by reported 13-F value include DEUTSCHE BANK AG\, ICAHN CARL C, OAKTREE CAPITAL MANAGEMENT, based on the most recent SEC filings. BLCO trades on the NYSE exchange and files with the SEC under CIK 1860742. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLCO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bausch & Lomb Corp directly from SEC EDGAR.

Revenue

Q1 2026

$1.2B

Net Income

Q1 2026

$-71.0M

Free Cash Flow

Q1 2026

$-68.0M

Operating Margin

Q1 2026

2.6%

ROIC

Q1 2026

0.3%

D/E Ratio

Q1 2026

0.79

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+6.5% YoY

$5.10BFY 2025

FY22 $3.77BFY23 $4.15BFY24 $4.79BFY25 $5.10B

Net Income

-13.6% YoY

$-360.0MFY 2025

FY22 $6.0MFY23 $-260.0MFY24 $-317.0MFY25 $-360.0M

Operating Income

-30.2% YoY

$113.0MFY 2025

FY22 $207.0MFY23 $130.0MFY24 $162.0MFY25 $113.0M

EPS (Diluted)

-13.3% YoY

$-1.02FY 2025

FY22 $0.02FY23 $-0.74FY24 $-0.90FY25 $-1.02

Total Assets

+4.1% YoY

$14.02BFY 2025

FY22 $11.14BFY23 $13.44BFY24 $13.47BFY25 $14.02B

Total Debt

+5.2% YoY

$5.08BFY 2025

FY22 $2.46BFY23 $4.59BFY24 $4.82BFY25 $5.08B

Op. Cash Flow

+22.0% YoY

$283.0MFY 2025

FY22 $345.0MFY23 $-17.0MFY24 $232.0MFY25 $283.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$5.10B +6.5%	$4.79B +15.6%	$4.15B +10.0%	$3.77B +0.1%	$3.77B +10.3%	$3.41B
Net Income	$-360.0M -13.6%	$-317.0M -21.9%	$-260.0M -4433.3%	$6.0M -96.7%	$182.0M +1111.1%	$-18.0M
Operating Income	$113.0M -30.2%	$162.0M +24.6%	$130.0M -37.2%	$207.0M -37.1%	$329.0M +26.5%	$260.0M
EPS (Diluted)	$-1.02 -13.3%	$-0.90 -21.6%	$-0.74 -3800.0%	$0.02 -96.2%	$0.52 +1140.0%	$-0.05
Total Assets	$14.02B +4.1%	$13.47B +0.2%	$13.44B +20.6%	$11.14B +3.0%	$10.82B	—
Total Debt	$5.08B +5.2%	$4.82B +5.1%	$4.59B +86.6%	$2.46B	$0.00	—
Operating Cash Flow	$283.0M +22.0%	$232.0M +1464.7%	$-17.0M -104.9%	$345.0M -60.5%	$873.0M +67.2%	$522.0M

AI Insight: BLCO Ratio Trends

BLCO's operating margins are recovering from a Q1 2025 trough but net profitability remains persistently negative across nearly every reported period.

• Operating margin rebounded sharply from -7.3% in Q1 2025 to 8.0% in Q4 2025, before dipping back to 2.6% in Q1 2026, suggesting seasonal volatility.

• Net profit margin has been negative in all but one quarter (Q3 2024: 0.3%), indicating structural below-the-line cost pressures.

• ROIC improved from -3.0% in Q1 2025 to 3.9% in Q4 2025, but fell back to 1.1% in Q1 2026, reflecting fragile capital efficiency.

⚠ D/E has crept up from 0.71 in Q3 2024 to 0.79 in Q1 2026 — modest leverage increase worth monitoring given persistent net losses.

⚠ Q1 2026 operating margin of 2.6% versus Q4 2025's 8.0% — whether this Q1 dip is seasonal or signals renewed margin compression is key.

Get alerted when BLCO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Bausch & Lomb Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BLCO

DEUTSCHE BANK AG\
$56.1M3,528,441 sh
ICAHN CARL C
$55.6M3,500,000 sh
OAKTREE CAPITAL MANAGEMENT LP
$53.8M3,382,739 sh
D. E. Shaw & Co., Inc.
$50.1M3,151,167 sh
GOLDENTREE ASSET MANAGEMENT LP
$42.2M2,660,508 sh
Silver Point Capital L.P.
$35.7M2,245,000 sh
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
$35.0M2,199,172 sh
CASPIAN CAPITAL LP
$31.8M1,999,043 sh
GLENVIEW CAPITAL MANAGEMENT, LLC
$30.4M1,910,496 sh
NOMURA HOLDINGS INC
$20.0M1,256,181 sh

Fund	Value	Shares
DEUTSCHE BANK AG\	$56.1M	3,528,441
ICAHN CARL C	$55.6M	3,500,000
OAKTREE CAPITAL MANAGEMENT LP	$53.8M	3,382,739
D. E. Shaw & Co., Inc.	$50.1M	3,151,167
GOLDENTREE ASSET MANAGEMENT LP	$42.2M	2,660,508
Silver Point Capital L.P.	$35.7M	2,245,000
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP	$35.0M	2,199,172
CASPIAN CAPITAL LP	$31.8M	1,999,043
GLENVIEW CAPITAL MANAGEMENT, LLC	$30.4M	1,910,496
NOMURA HOLDINGS INC	$20.0M	1,256,181

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BLCO on your watchlist

Track score changes the day Bausch & Lomb Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BLCO a good stock to buy?

13F Pro's AI-powered analysis of Bausch & Lomb Corp (BLCO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BLCO are available on the BLCO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BLCO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BLCO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bausch & Lomb Corp's investment landscape.